摘要
Abstract
Objective To evaluate the acute coronary syndrome percutaneous coronary intervention(PCI)in patients with domestic or imported clopidogrel economics and compliance. Methods Included 168 patients before PCI therapy in patients with coronary heart disease, were randomly divided into two groups,both in the corresponding thrombolysis,antiplatelet,anti myocardial ischemia after drug treatment given to the PCI revascularization.The treatment group of 84 cases with domestic clopidogrel therapy,84 cases in the control group using imported clopidogrel therapy.Results 21 d after fol ow-up,the treatment group and the control group of major cardiovascular event rates were 3.6%,stent thrombosis rate was 5.9%,PAR were(48 ± 7)%,(49 ± 8)%,the difference was not statistical y significant(P>0.05);long term fol ow up of 12 months,the treatment group and the control group of major cardiovascular event rates were 8.3%,9.5%,and 12 months after treatment PAR were(49 ± 8)%,(47 ± 8)%,the difference was not statistical y significant(P>0.05);with the control treatment group cost-benefit respectively 29.6,80.8,to increase the cost-effectiveness ratios were 1.0,2.7.Conclusion Domesticclopidogrel after PCI in acute phase reduced risk of cardiovascular events, ong-term prevention of recurrent cardiovascular events,similar to the imported clopidogrel.But the cost-benefit ratio, domestic clopidogrel has a better economy.关键词
国产氯吡格雷/经皮冠状动脉介入治疗/进口氯吡格雷/成本-效益分析Key words
Domestic clopidogrel/Percutaneous coronary intervention/Imported clopidogrel/Cos-Benefit analysis分类
医药卫生
